KIT and melanoma: Conversely, another study reported growth inhibition of B16F10 mouse melanoma cells in vitro and in vivo (Table 1) [38], but this did not translate clinically, and no objective responses were observed with imatinib in advanced metastatic melanoma based on the relative expression densities of receptor tyrosine kinases c-KIT and PDGF-R (Table 2) [39].